Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
RESEARCH TOOLSreports
Holding TSE:GUD?
Track your performance easily
Knight Therapeutics (GUD) Ownership Overview
34.78% Insiders
1.99% Mutual Funds
0.09% Other Institutional Investors
0.81% ETFs
62.34% Public Companies and
Individual Investors
The ownership structure of Knight Therapeutics (TSE:GUD) stock is a mix of institutional, retail, and individual investors. Approximately 2.88% of the company’s stock is owned by Institutional Investors, 34.78% is owned by Insiders, and 62.34% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Nov 16, 2024 | Sime Armoyan Shareholder, >10% Owner | xxxxxxxxxxxxx | C$513620 |
| Nov 12, 2024 | Samira Sakhia President & Chief Executive Officer | xxxxxxxxxxxxx | C$103000 |
| Sep 23, 2024 | Sime Armoyan Shareholder, >10% Owner | xxxxxxxxxxxxx | C$1839000 |
| Aug 20, 2024 | Amal Khouri Chief Business Officer | xxxxxxxxxxxxx | C$54507 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 21,764,635 | Insider | 21.59% | 81,095,030 | |
| 12,466,200 | Insider | 12.37% | 46,449,061 | |
| 1,256,903 | Institution | 1.25% | 4,683,221 | |
| 411,025 | Institution | 0.41% | 1,531,479 | |
| 358,232 | Institution | 0.36% | 1,334,772 | |
| 320,603 | Institution | 0.32% | 1,194,567 | |
| 286,651 | Institution | 0.28% | 1,068,062 | |
| 278,278 | Insider | 0.28% | 1,036,864 | |
| 268,178 | Insider | 0.27% | 999,231 | |
| 157,161 | Insider | 0.16% | 585,582 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 1,256,903 | Institution | 1.25% | 4,683,221 | |
| 411,025 | Institution | 0.41% | 1,531,479 | |
| 286,651 | Institution | 0.28% | 1,068,062 | |
| 26,600 | Institution | 0.03% | 99,112 | |
| 19,818 | Institution | 0.02% | 73,842 | |
| 5,400 | Institution | <0.01% | 20,120 | |
| 2,400 | Institution | <0.01% | 8,942 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 184,954 | Institution | 0.18% | 699,937 | |
| 108,965 | Institution | 0.11% | 413,441 | |
| 70,949 | Institution | 0.07% | 268,498 | |
| 69,716 | Institution | 0.07% | 263,832 | |
| 62,333 | Institution | 0.06% | 235,892 | |
| 41,274 | Institution | 0.04% | 218,339 | |
| 18,505 | Institution | 0.02% | 104,923 | |
| 22,855 | Institution | 0.02% | 86,848 | |
| 20,346 | Institution | 0.02% | 77,008 | |
| 9,719 | Institution | <0.01% | 51,414 |
FAQ
Who Owns Knight Therapeutics (TSE:GUD)?
According to the latest TipRanks data, approximately 0.09% of the company's stock is held by institutional investors, 34.78% is held by insiders, and 62.34% is held by retail investors.
What percentage of Knight Therapeutics (TSE:GUD) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.09% of Knight Therapeutics (TSE:GUD) stock is held by institutional investors.
What percentage of Knight Therapeutics (TSE:GUD) stock is held by retail investors?
According to the latest TipRanks data, approximately 62.34% of Knight Therapeutics (TSE:GUD) stock is held by retail investors.
Who owns the most shares of Knight Therapeutics (TSE:GUD)?
Jonathan Ross Goodman owns the most shares of Knight Therapeutics (TSE:GUD).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.